Search results for " Effectiveness"

showing 10 items of 263 documents

Transformational Leadership, Task-Involving Climate, and Their Implications in Male Junior Soccer Players: A Multilevel Approach

2019

Despite the well-known positive consequences of transformational coaches in sport, there is still little research exploring the mechanisms through which coaches&rsquo

MaleMediation (statistics)AdolescentHealth Toxicology and Mutagenesismedia_common.quotation_subjectApplied psychologyeducationlcsh:MedicinePersonal Satisfactionmultilevel SEMOutcome (game theory)ArticleTask (project management)03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesPerception0502 economics and businesstransformational leadershipHumansLeadership stylemedia_commonMotivationLeadership effectivenessbiologyAthleteslcsh:R05 social sciencesPublic Health Environmental and Occupational Health030229 sport sciencesbiology.organism_classificationsoccerLeadershipTransformational leadershipjunior playersAthletesmotivational climatePsychologyhuman activities050203 business & managementpsychological phenomena and processes
researchProduct

Short-term cost-effectiveness of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: Results from the SOPHO-NET trial

2015

Abstract Background To investigate the short-term cost-effectiveness of cognitive-behavioral therapy (CBT) and psychodynamic therapy (PDT) compared to waiting list (WL). Methods The analysis was conducted alongside the SOPHO-NET multi-center efficacy trial. Patients were randomly assigned to CBT ( n =209), PDT ( n =207), or WL ( n =79). Resource use was assessed prior and during treatment to determine direct and absenteeism costs. Unadjusted incremental cost-effectiveness ratios (ICERs) were calculated based on remission and response rates. To visualize statistical uncertainty, cost-effectiveness acceptability curves (CEACs) were constructed based on adjusted net-benefit regression. Differe…

MaleMental Health Servicesmedicine.medical_specialtyTime FactorsWaiting ListsCost effectivenessCost-Benefit Analysismedicine.medical_treatmentPsychological interventionGroup psychotherapyIndirect costsWillingness to paymedicineHumansPsychiatryhealth care economics and organizationsCognitive Behavioral TherapyMiddle Aged3. Good healthCognitive behavioral therapyPsychiatry and Mental healthClinical PsychologyTreatment OutcomePhobic DisordersEconomic evaluationAbsenteeismPhysical therapyFemalePsychologyJournal of Affective Disorders
researchProduct

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2014

Abstract Background We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy. Methods Cost-effectiveness analysis performed according to data from the available published literature. The target population was composed of untreated Caucasian patients, aged 50 years, with genotype 1 chronic hepatitis C, and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian Nati…

MaleNational Health ProgramsCost effectivenessCost-Benefit AnalysisHepacivirusNational Health ProgramHepacivirusPharmacologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundQuality-Adjusted Life YearMedicineSettore SECS-S/05 - Statistica SocialeMultivariate AnalysiBoceprevirSettore MED/12 - GastroenterologiabiologyMedicine (all)GastroenterologyMiddle AgedRecombinant ProteinMarkov ChainsRecombinant ProteinsModels EconomicTreatment OutcomeItalyDrug Therapy CombinationFemaleQuality-Adjusted Life YearsSettore SECS-S/01 - StatisticaViral loadHumanmedicine.medical_specialtyGenotypeProlineAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineBoceprevirRibavirinHumansCost-Benefit AnalysiAntiviral AgentHepaciviruPeg-interferonHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C ChronicMarkov Chainbiology.organism_classificationQuality-adjusted life yearchemistryCost-effectiveneMultivariate AnalysisQuality of LifeCost-effectivenessbusiness
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update

2018

Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease …

MaleOncologymedicine.medical_specialtyCombination therapyCost effectivenessUrologyAntineoplastic AgentsDiseaselaw.invention03 medical and health sciencesProstate cancerchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineBone Density Conservation Agentsbusiness.industryAbiraterone acetateProstatic NeoplasmsBone metastasismedicine.diseaseZoledronic acidOncologychemistry030220 oncology & carcinogenesisDrug Therapy Combinationbusinessmedicine.drugUrologic Oncology: Seminars and Original Investigations
researchProduct

Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose

2003

Breakthrough pain is normally severe in intensity and has a rapid onset. The availability of supplemental doses of opioids (rescue medication) in addition to the continuous analgesic medication is the main treatment suggested to manage these pain flares. The intravenous (i.v.) route may provide analgesia fast enough, but has never been assessed in clinical studies. The aim of this open-label study was to verify the safety and effectiveness of an i.v. dose equal to one-fifth the calculated equianalgesic total daily dose in advanced cancer patients with episodic pain. A consecutive sample of 48 cancer patients treated with oral morphine, who reported an acceptable basal analgesia and reported…

MalePalliative careExacerbationSafety and effectiveness of intravenous morphineAnalgesicPainDrug Administration ScheduleOral administrationNeoplasmsmorphine doseMedicineHumansAdverse effectGeneral NursingDose-Response Relationship DrugMorphineepisodic (breakthrough) painbusiness.industryPalliative CareMiddle AgedEquianalgesicAnalgesics OpioidAnesthesiology and Pain MedicineAnesthesiaInjections IntravenousMorphineFemaleNeurology (clinical)businessCancer painmedicine.drug
researchProduct

A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis

1987

In a long-term multicenter open trial involving 10 general practitioners, the efficacy and tolerance of S-adenosylmethionine (SAMe) were studied for 24 months in 108 patients with osteoarthritis of the knee, hip, and spine. At the end of the 24-month observation period, 97 of the patients were still in the study. The patients received 600 mg of SAMe daily (equivalent to three tablets of 200 mg each) for the first two weeks and thereafter 400 mg daily (equivalent to two tablets of 200 mg each) until the end of the 24th month of treatment. Separate evaluations were made for osteoarthritis of the knee, hip, cervical spine, and dorsal/lumbar spine. The severity of the clinical symptoms (morning…

MaleS-Adenosylmethioninemedicine.medical_specialtyClinical effectivenessOsteoarthritisOsteoarthritisHumansMedicineLongitudinal StudiesAdverse effectAgedClinical Trials as TopicPsychological TestsDepressionbusiness.industryAnti-Inflammatory Agents Non-SteroidalMorning stiffnessGeneral MedicineMiddle Agedmedicine.diseaseCervical spineSurgeryClinical trialFemaleLumbar spineOpen labelbusinessThe American Journal of Medicine
researchProduct

Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multicenter, three-armed randomized…

2017

Depression is one of the most common mental disorders and will become one of the leading causes of disability in the world. Internet-based CBT programs for depression have been classified as well established following the American Psychological Association criteria for empirically supported treatments. The aim of this study is to analyze the cost effectiveness at 12-month follow-up of the Internet-based CBT program Smiling is fun with (LITG) and without psychotherapist support (TSG) compared to usual care. The perspective used in our analysis is societal. A sample of 296 depressed patients (mean age of 43.04 years; 76% female; BDI-II mean score = 22.37) from primary care services in four Sp…

MaleSpanish PeopleEconomicsPsychological interventionSocial SciencesSeverity of Illness Indexlaw.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Learning and Memory0302 clinical medicineHispanoamericanosEthnicitiesPsychologyAnálisis de intención de tratarlcsh:Sciencemediana edadancianoDepressionAntidepressantsadulto:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Humanosadulto joven:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic::Intention to Treat Analysis [Medical Subject Headings]Psicoterapia:Information Science::Information Science::Computing Methodologies::Computer Systems::Computer Communication Networks::Internet [Medical Subject Headings]medicine.medical_specialtyEvidence-based practiceGrupos control03 medical and health sciences:Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis [Medical Subject Headings]Drug TherapySeverity of illnessHumans:Persons::Persons::Age Groups::Adult [Medical Subject Headings]psicoterapiaAgedPharmacologyDepressive DisorderDepressive Disorder MajorInternetPrimary Health CareMood Disorderslcsh:RBiology and Life SciencesSonrisa030227 psychiatryHealth CareAnálisis costo-beneficio:Check Tags::Female [Medical Subject Headings]Economic evaluationlcsh:QPopulation GroupingsNeuroscienceGerontologyFinancial ManagementCost effectivenessCost-Benefit Analysishumanosadolescentelcsh:MedicineTrastorno depresivoRandomized controlled triallawDepresiónMedicine and Health Sciences030212 general & internal medicineMultidisciplinaryAdultoPharmaceuticsresultado del tratamientoFemeninoDrugsCost-effectiveness analysisMiddle AgedTelemedicineTreatment OutcomeSociedades científicasFemale:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Communication::Nonverbal Communication::Facial Expression::Smiling [Medical Subject Headings]Estudios de seguimiento:Persons::Persons::Population Groups::Ethnic Groups::Hispanic Americans [Medical Subject Headings]telemedicinaResearch ArticleAdultAdolescent:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings]:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychotherapy [Medical Subject Headings]Cost-Effectiveness AnalysisMEDLINEYoung Adulttrastorno depresivoAtención primaria de saludMental Health and PsychiatryIndirect CostsmedicineLearningíndice de gravedad de la enfermedadPrimary Care:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Depressive Disorder [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::Societies::Societies Scientific [Medical Subject Headings]Cognitive Behavioral Therapybusiness.industryCognitive Psychology:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Follow-Up Studies [Medical Subject Headings]Economic AnalysisPsychotherapyPeople and PlacesPhysical therapyCognitive Science:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings]businessFinance
researchProduct

Cost effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

2013

Background & Aims Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC. Methods The available published literature provided the data source. The target population was made up of previously treated Caucasian patients with G1 CHC and these were evaluated over a lifetime horizo…

MaleTVRCost effectivenessCost-Benefit AnalysisPIPeginterferon-alfaBOCHepacivirusBOC Boceprevir CHC Cost-effectiveness DT G1 ICER NR PAR PI PegIFN RBV RR TVR Telaprevir boceprevir chronic hepatitis C dual therapy genotype 1 incremental cost-effectiveness ratio non-response partial response pegylated interferon protease inhibitors relapse ribavirin telaprevirTelaprevirTelaprevirchemistry.chemical_compoundPegylated interferonnon-responseboceprevirincremental cost-effectiveness ratioRBVTreatment FailureDThealth care economics and organizationsRandomized Controlled Trials as Topicrelapsecost effectivenessICERMiddle AgedMarkov ChainsModels EconomicItalyQuality-Adjusted Life YearsSettore SECS-P/02 - politica economicaSettore SECS-S/01 - StatisticaIncremental cost-effectiveness ratioOligopeptidesmedicine.drugmedicine.medical_specialtyGenotypeProlineribavirinSettore MED/12 - GASTROENTEROLOGIAprotease inhibitorsNRRRAntiviral AgentsInternal medicineBoceprevirG1medicineHumanschronic hepatitis Cpegylated interferongenotype 1Hepatologybusiness.industryRibavirindual therapyHepatitis C ChronicQuality-adjusted life yearSurgeryCHCPegIFNchemistryCost-effectivenesspartial responsebusinessPAR
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct